Sophia Z. Humphreys, PharmD, MHA
Sophia Z. Humphreys, PharmD, MHA, BCBBS, is the director of system pharmacy formulary management & clinical programs at Sutter Health in Sacramento, California. She has nearly 20 years of specialized experience in the pharmaceutical industry and is an expert in pharmacy regulatory compliance, US Pharmacopeia General Chapter <797>/<800> pharmacy regulations, clinical education, long-term care pharmacy service, and pharmaceutical waste management. She has a strong background in strategic planning and project management. Prior to her current position, she served as the director of system pharmacy clinical services at Providence St. Joseph Health.
Articles
Resources for Patients and Providers on Adalimumab Biosimilars
Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.
The Role of Nurses and Support Personal in Educating Patient on Adalimumab Biosimilars
Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars.
Common Questions From Patients About Adalimumab Biosimilars
Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.
Copay Assistance Programs for Adalimumab Biosimilars
Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.
The Role of Health Care Providers on Encouraging Adalimumab Biosimilar Use
Healthcare providers in inflammatory diseases talk about the role they have on encouraging adalimumab biosimilar use in clinical practice.
Clinical Experience With Initiating Adalimumab Biosimilars
Specialists in rheumatology, dermatology and gastrointestinal disease share their clinical experience on initiating or switching their patients on adalimumab biosimilars.
Switching From Adalimumab to a Biosimilar
Specialists in rheumatology, dermatology and gastrointestinal disease discuss the evidence on efficacy and safety on switching patient to an adalimumab biosimilar.
Selecting Between Adalimumab Biosimilars for Your Patients
Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.
Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice
A clinical pharmacist and specialists in rheumatology, dermatology, and gastrointestinal disease share strategies in how to increase the uptake of adalimumab biosimilar among providers.
The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars
A clinical pharmacist discusses the role of pharmacy benefit managers and payers in accessibility of adalimumab biosimilars.
Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings
Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.
The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases
Specialists in rheumatology, dermatology and gastrointestinal disease discuss clinical trials that have shown safety and efficacy of adalimumab biosimilars in inflammatory diseases.
The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval
Drs Lio, Botsoglou, and Alexrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.
Contributor: The US Biosimilar Market Outlook for 2023
January 24th 2023Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health in Sacramento, California, details the regulatory decisions from 2022, what's to come in 2023, and how the US biosimilars market is expected to shift over the next 5 years.
Hospital System Boosts Biosimilar Use With EHR System
April 4th 2020Providence St. Joseph Health used Toyota’s Kaizen system of nonvariance and standardization to build a model that increased use of biosimilars among physicians. The model employed the electronic health record system to guide physicians toward use of biosimilars, thereby increasing savings.
